Display options
Cite
Zhai X, Han W, Wang M, et al. Exogenous supplemental NAD+ protect myocardium against myocardial ischemic/reperfusion injury in swine model. Am J Transl Res. 2019;11(9):6066-6074
Zhai, X., Han, W., Wang, M., Guan, S., & Qu, X. (2019). Exogenous supplemental NAD+ protect myocardium against myocardial ischemic/reperfusion injury in swine model. American journal of translational research, 11(9), 6066-6074.
Zhai, Xinrong, et al. "Exogenous supplemental NAD+ protect myocardium against myocardial ischemic/reperfusion injury in swine model." American journal of translational research vol. 11,9 (2019): 6066-6074.
Zhai X, Han W, Wang M, Guan S, Qu X. Exogenous supplemental NAD+ protect myocardium against myocardial ischemic/reperfusion injury in swine model. Am J Transl Res. 2019 Sep 15;11(9):6066-6074. eCollection 2019. PMID: 31632574; PMCID: PMC6789262.
Copy Download .nbib Format: NLM
Share it on

Am J Transl Res. 2019 Sep 15;11(9):6066-6074. eCollection 2019.

Exogenous supplemental NAD+ protect myocardium against myocardial ischemic/reperfusion injury in swine model.

American journal of translational research

Xinrong Zhai, Wenzheng Han, Ming Wang, Shaofeng Guan, Xinkai Qu

Affiliations

  1. Department of Cardiology, Huadong Hospital Affiliated to Fudan University Shanghai, China.
  2. Shanghai Key Laboratory of Clinical Geriatric Medicine Shanghai, China.

PMID: 31632574 PMCID: PMC6789262

Abstract

Acute myocardial infarction is one of the leading causes of deaths worldwide. Although ameliorative therapies against ischemic injury have remarkably reduced death rates among patients, they are inevitably complicated by reperfusion injury. Therefore, it is essential to explore other approaches to reduce ischemia/reperfusion injury (IRI). Modulating the levels of nicotinamide adenine dinucleotide (NAD+) is a promising therapeutic strategy against some aging-related diseases. The aim of this study was to determine the role of NAD+ in a swine model of myocardial IRI. Fourteen Bama miniature pigs were subjected to 90 min transluminal balloon occlusion, and then randomly administrated with 20 mg/kg NAD+ or saline before reperfusion. Emission computerized tomography (ECT) was performed immediately and 4 weeks after reperfusion, and the cardiac tissues were analyzed histologically. In addition, the levels of cardiac function markers and the pro-inflammatory cytokines IL-1β and TNF-α were also measured. NAD+ administration markedly reduced myocardial necrosis, enhanced glucose metabolism, and promoted cardiac function recovery. The extent of inflammation was also reduced in the NAD+ treated animals, and corresponded to less cardiac fibrosis and better ventricular compliance. Thus, NAD+ supplementation protected the myocardium from IRI, making it a promising therapeutic agent against acute myocardial ischemic disease.

AJTR Copyright © 2019.

Keywords: Myocardial; NAD+; glucose metabolism; ischemia/reperfusion injury; necrosis

Conflict of interest statement

None.

References

  1. Am J Physiol Endocrinol Metab. 2007 May;292(5):E1288-94 - PubMed
  2. Nat Rev Cancer. 2012 Nov;12(11):741-52 - PubMed
  3. Circulation. 2003 Feb 25;107(7):1046-52 - PubMed
  4. Int J Cardiovasc Imaging. 2002 Feb;18(1):539-42 - PubMed
  5. J Biol Chem. 2001 Jan 26;276(4):2571-5 - PubMed
  6. PLoS Biol. 2015 Sep 10;13(9):e1002243 - PubMed
  7. Physiol Rev. 2008 Jul;88(3):841-86 - PubMed
  8. J Nutr Biochem. 2018 May;55:209-218 - PubMed
  9. Cell Metab. 2015 Jul 7;22(1):31-53 - PubMed
  10. Neurotoxicology. 2014 Jan;40:65-74 - PubMed
  11. J Am Coll Cardiol. 2015 Apr 14;65(14):1454-71 - PubMed
  12. Biochem J. 2011 Oct 15;439(2):341-8 - PubMed
  13. Am J Cardiol. 2010 May 15;105(10):1371-1377.e1 - PubMed
  14. Mol Cell. 2007 Oct 26;28(2):277-90 - PubMed
  15. J Biol Chem. 2004 Apr 30;279(18):18895-902 - PubMed
  16. Circulation. 2008 May 20;117(20):2670-83 - PubMed
  17. Nat Rev Cardiol. 2014 May;11(5):255-65 - PubMed
  18. Br J Pharmacol. 2015 Oct;172(20):4817-32 - PubMed
  19. Cell Metab. 2012 Sep 5;16(3):290-5 - PubMed
  20. Nat Rev Endocrinol. 2015 Sep;11(9):535-46 - PubMed
  21. Cardiovasc Res. 2012 May 1;94(2):359-69 - PubMed
  22. Mol Pharmacol. 2011 Dec;80(6):1136-46 - PubMed
  23. Cancer Cell. 2015 Dec 14;28(6):773-784 - PubMed
  24. Nucl Med Biol. 2011 Aug;38(6):819-25 - PubMed
  25. Endocr Rev. 2010 Apr;31(2):194-223 - PubMed
  26. J Biol Chem. 2012 Jul 27;287(31):25770-81 - PubMed
  27. Front Physiol. 2014 Sep 29;5:352 - PubMed
  28. J Am Assoc Lab Anim Sci. 2010 May;49(3):344-51 - PubMed
  29. Trends Endocrinol Metab. 2012 Sep;23(9):420-8 - PubMed
  30. Am J Physiol. 1979 Sep;237(3):E214-23 - PubMed
  31. Diabetes. 2013 Oct;62(10):3404-17 - PubMed
  32. Am J Cardiol. 2013 May 15;111(10):1394-400 - PubMed
  33. Nat Rev Mol Cell Biol. 2012 Mar 07;13(4):225-238 - PubMed
  34. Basic Res Cardiol. 2016 Mar;111(2):13 - PubMed
  35. J Clin Invest. 2013 Jan;123(1):92-100 - PubMed
  36. Mol Cell Endocrinol. 2015 Sep 5;412:65-72 - PubMed
  37. Am J Transl Res. 2016 Aug 15;8(8):3342-50 - PubMed
  38. J Mol Cell Cardiol. 1993 Mar;25(3):261-76 - PubMed
  39. Circ Res. 2009 Aug 28;105(5):481-91 - PubMed
  40. Cell Metab. 2014 Dec 2;20(6):926-7 - PubMed
  41. Trends Cell Biol. 2016 Apr;26(4):249-261 - PubMed
  42. Mol Cell Biol. 2009 Aug;29(15):4116-29 - PubMed
  43. Circulation. 1999 Mar 23;99(11):1492-8 - PubMed
  44. J Neurosci. 2010 Feb 24;30(8):2967-78 - PubMed
  45. J Biol Chem. 2011 Mar 18;286(11):9856-64 - PubMed
  46. Cell Metab. 2011 Oct 5;14(4):528-36 - PubMed
  47. Cell Metab. 2011 Apr 6;13(4):461-468 - PubMed
  48. Circulation. 2006 Oct 17;114(16):1721-8 - PubMed

Publication Types